AstraZeneca teams up with Scorpion Therapeutics to develop cancer treatments
Over the current book year the company from Cambridge's total revenue could be around 42.99 billion GBp (consensus estimates). This is rather significant more than 2021's revenue of 37.42 billion GBp.
Historical revenues and results Astrazeneca plus estimates 2021
The analysts expect for 2021 a net profit of 10.02 billion GBp. Most of the analysts anticipate on a profit per share of 666 GBp. So the price/earnings-ratio equals 13.39.
Huge dividend Astrazeneca
Analysts expect a dividend of 291 GBp per share. Thus the dividend yield equals 3.26 percent. The average dividend yield of the pharmaceutical companies equals a low 1.37 percent.Latest estimates around 9563 GBp
The latest 3 recommendations for the pharmaceutical company were provided by Liberum, Morgan Stanley and Berenberg.Based on the current number of outstanding shares Astrazeneca 's market capitalization 11706.38 billion GBp. 23
At 14.37 the stock trades 0.73 percent lower at 8918 GBp.Historical stock prices Astrazeneca
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
